Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:05 ET
|
Longeveron
Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
April 18, 2024 16:05 ET
|
Longeveron
Longeveron raises $11.4 million in gross proceeds from warrent exercise offering and public offering.
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
April 15, 2024 08:30 ET
|
Longeveron
Data from Longeveron's CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B in Alzheimer’s Disease has been accepted for two presentations at AAIC.
Longeveron Announces Closing of $5.2 Million Public Offering
April 11, 2024 17:17 ET
|
Longeveron
Longeveron announces closing of previously announced public offering, raising $5.25 million in gross proceeds.
Longeveron Announces Pricing of $5.25 Million Public Offering
April 08, 2024 14:15 ET
|
Longeveron
Longeveron prices $5.15 million public offering with certain board member and insider participation.
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
April 08, 2024 08:30 ET
|
Longeveron
CEO Letter to Shareholders. Update on overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.
LGVN SHAREHOLDER ALERT: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Longeveron Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – LGVN
November 01, 2021 19:45 ET
|
The Rosen Law Firm PA
NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or...